Roche.com: FDA grants Breakthrough Therapy Designation for Roche's balovaptan in autism spectrum disorder

Basel, 29 January 2018

FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder Balovaptan has the potential to be the first pharmacotherapy to help improve core social interaction and communication in people with autism spectrum disorder Second FDA Breakthrough Therapy Designation for a Roche neuroscience medicine

Roche

Read the full article at the original source

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.